DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

This study tests a new combination of treatments — including two viral therapy agents (DB107-RRV and DB107-FC) — alongside standard radiation and chemotherapy for patients newly diagnosed with high-grade brain tumors (glioma or glioblastoma). Researchers want to see whether adding these new agents improves outcomes. **You may be eligible if...** - You are 18–75 years old with a newly diagnosed high-grade brain tumor (astrocytoma or glioblastoma) that has not yet been treated - Your tumor can be removed at least 80% through surgery - You are in reasonably good physical condition (Karnofsky score ≥70) - Your blood counts, liver, and kidney function are adequate **You may NOT be eligible if...** - You have previously received surgery, radiation, or chemotherapy for a brain tumor - You have a serious infection or uncontrolled medical condition - You are pregnant or breastfeeding - Your performance level is too low to safely undergo treatment Talk to your doctor to see if this trial is right for you.